Akcea e Ionis reciben una opinión positiva del CHMP de la UE para WAYLIVRATM (volanesorsen)
06. März 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Massachusetts, y CARLSBAD, California, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ: AKCA), una filial de Ionis Pharmaceuticals, Inc., e Ionis Pharmaceuticals, Inc....
Akcea und Ionis erhalten positive Stellungnahme des CHMP zu WAYLIVRATM (Volanesorsen)
06. März 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Massachusetts und CARLSBAD, Kalifornien, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), ein Tochterunternehmen von Ionis Pharmaceuticals, Inc. und Ionis...
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
01. März 2019 07:45 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:...
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
28. Februar 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018
26. Februar 2019 16:05 ET
|
Akcea Therapeutics, Inc.
TEGSEDI™ (inotersen) commercially available in United States, European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million Conference...
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
25. Februar 2019 01:15 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
Phase 3 planning and initiation activities underway Akcea earns $150M license fee BOSTON and CARLSBAD, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an...
Akcea Therapeutics to Present at Upcoming Investor Conferences
20. Februar 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast
13. Februar 2019 16:05 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February...
Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting
29. November 2018 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that it will present the long-term analyses of the...
Akcea присоединяется к первому Всемирному дню знаний о семейном синдроме хиломикронемии.
28. November 2018 15:57 ET
|
Akcea Therapeutics, Inc.
Бостон, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Akcea присоединяется к первому Всемирному дню знаний о семейном синдроме хиломикронемии. Сообщество ставит целью повышения знаний в обществе о тяжести...